US04317A1079
US04317A1079
Artiva Biotherapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 339.3M EUR | 474.19M EUR | 159.18M EUR | 105.51M EUR |
Enterprise Value | -7.09M EUR | 182.59M EUR | 148.48M EUR | 89.76M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -2.66x | -- | -- | -- |
Price to Sales | -- | -- | -- | -- |
Price to Book | 0.97x | 1.36x | 1.81x | 0.96x |
EV/Revenue | -- | -- | -- | -- |
EV/EBITDA | 0.08x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -13.1% | -16.22% | -50.37% | -55.9% |